Profile Technologies (PRTK) Narrows Q3 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. NXPI
4. BA
5. STX
6. V
7. CSGP
8. LSTR
9. UPS
10. KIDS

Go back to Profile Technologies (PRTK) Narrows Q3 Loss

Paratek Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial and Operating Results

November 12, 2015 7:01 AM EST

Enrolling Patients in Phase 3 Registration Study of Omadacycline in Community Acquired Bacterial Pneumonia Granted FDA Fast Track Status for Omadacycline Advancing Phase 3 Registration Study of Omadacycline in Acute Bacterial Skin and Skin Structure Infections According to Plan

BOSTON, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results for the quarter ended September 30, 2015. This quarter the company reported a net loss attributable to common... More

Paratek Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial and Operating Results

November 12, 2015 7:00 AM EST

Enrolling Patients in Phase 3 Registration Study of Omadacycline in Community Acquired Bacterial Pneumonia Granted FDA Fast Track Status for Omadacycline Advancing Phase 3 Registration Study of Omadacycline in Acute Bacterial Skin and Skin Structure Infections According to Plan

BOSTON, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results for the quarter ended September 30, 2015. This quarter the company reported a net loss attributable to common... More